Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ODTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Odyssey Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Odyssey Therapeutics, Inc.
Upcoming catalysts 2
Event history 15
Past FDA Catalysts and PDUFA Decisions
How ODTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-06 | OD-003 (TNFR2 agonist) | Pre-clinical data presentation | Pre-clinical |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OD-07656 Small MoleculesNCT06850727 | Ulcerative Colitis (UC) | Phase 2 | RECRUITING | 57 | Nov 1, 2026 | ||||||
| OD-001 Small MoleculesNCT07900607 | Undisclosed | Phase 1 | RECRUITING | 8 | Jan 1, 2027 | ||||||
| OD-07656 Small MoleculesCompletedNCT06206811 | Inflammatory Bowel Diseases | Phase 1 | COMPLETED | 101 | Nov 25, 2024 | ||||||
| PRV-002 Small MoleculesCompletedNCT05033444 | Traumatic Brain Injury (TBI) | Phase 1 | COMPLETED | 40 | Sep 13, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every ODTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OD-001 | ulcerative colitis | Phase 2a | 2026-10-20 | mean reduction modified mayo score: 2.4 points; p value: <0.001; clinical remission 20mg BID: 27%; clinical response 20mg BID: 61%; symptomatic remission 20mg BID: 49%; clinical remission 10mg BID: 20%; clinical response 10mg BID: 40%; symptomatic remission 10mg BID: 27%; symptomatic remission week 2 20mg BID: 21%; clinical remission advanced naïve: 29%; clinical remission advanced experienced: 23%Read More | Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TPG GP A, LLCFormer 10% Owner | Other | 423,111 423,111 held | $0.00 | 05/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ODTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.2 % (20 %) | 66.69 M | 3.00 M |
Ownership Trends
ODTX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How ODTX ranks across every disease it competes in
ODTX News
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
Odyssey Therapeutics published a study showing TNFR2 agonism expands regulatory T cells and reduces inflammation in preclinical models. The research supports OD-003, the company’s investigational drug, as a potential treatment for autoimmune diseases. IND-enabling studies for OD-003 are expected to finish in the first quarter of 2027.
Read more →Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics reported strong progress in its pipeline, particularly for OD-001, which shows enhanced clinical proof of concept in ulcerative colitis. The company completed IND-enabling studies for OD-002, a novel SLC15A4 inhibitor. Financially, Odyssey holds $387 million, expected to support operations through mid-2028, despite a net loss of $53.1 million in Q3 2026.
Read more →Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
Odyssey Therapeutics announced positive results from its Phase 2a trial of OD-001 for ulcerative colitis, showing significant clinical efficacy and a favorable safety profile. The trial met its primary endpoint with a notable reduction in the modified Mayo score. The company plans to advance OD-001 into further clinical trials, including a Phase 2b monotherapy trial.
Read more →Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
Odyssey Therapeutics has announced a Phase 2a trial to evaluate OD-001 in combination with vedolizumab for treating moderate-to-severe ulcerative colitis. The trial will assess the efficacy and safety of this combination therapy, which targets both innate and adaptive immune responses. Results are expected in the second half of 2027, following a 12-week induction period.
Read more →Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Odyssey Therapeutics announced that additional results from the OD-001 Phase 2a trial will be presented at UEG Week 2026. The oral presentation, led by Dr. Bruce Sands, will focus on the safety and efficacy of OD-001 in patients with moderate to severe ulcerative colitis. A conference call will follow to discuss further data from the trial.
Read more →Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23. The event will be accessible via a live webcast and will feature members of the management team discussing the company's innovative approaches to treating autoimmune and inflammatory diseases. Odyssey aims to develop targeted therapies that address unmet medical needs.
Read more →Odyssey Therapeutics to Participate in Upcoming Investor Conferences
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in September 2026. These events include the Cantor Global Healthcare Conference, the Morgan Stanley Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference. The company aims to showcase its innovative approach to treating autoimmune and inflammatory diseases.
Read more →Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec SE has partnered with Odyssey Therapeutics to enhance drug discovery for autoimmune and inflammatory diseases. This collaboration will utilize Evotec's AI-enabled platform and advanced screening capabilities to identify new small molecule drug candidates. The goal is to expedite the development of innovative therapies that address significant unmet medical needs.
Read more →Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics reported its Q2 2026 financial results, highlighting positive proof-of-concept data for OD-001. The company plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab later this year. With $433.1 million in cash, Odyssey is well-positioned to fund operations into 2028. The company also plans to file a clinical trial application for OD-002 by year-end.
Read more →Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Odyssey Therapeutics reported positive clinical proof-of-concept data for its oral RIPK2 scaffolding inhibitor, OD-001, in a Phase 2a trial for ulcerative colitis. The company has a strong financial position with $464 million expected to support operations through 2028. Odyssey plans to advance OD-001 into late-stage development and initiate additional trials in the near future.
Read more →Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
Odyssey Therapeutics has announced the pricing of its upsized initial public offering, selling 15.5 million shares at $18.00 each. The offering, which could raise approximately $304 million, includes a concurrent private placement. Trading is expected to begin on the Nasdaq Capital Market under the ticker 'ODTX' on May 8, 2026.
Read more →Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board
Odyssey Therapeutics has appointed Dr. H. Martin Seidel to its Scientific Advisory Board. Dr. Seidel brings decades of experience in drug discovery and development, having held leadership roles at IFM Therapeutics and Novartis. His expertise is expected to enhance Odyssey's efforts in advancing its clinical programs targeting autoimmune and inflammatory diseases.
Read more →Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
Odyssey Therapeutics has appointed Jolie M. Siegel as Executive Vice President and General Counsel. Siegel will oversee legal, compliance, governance, and risk management functions, playing a key role in supporting the company's growth and strategic opportunities. With over two decades of experience in biotechnology and life sciences, her leadership is expected to enhance Odyssey's capabilities in advancing therapies for autoimmune diseases.
Read more →Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Nonclinical Development
Odyssey Therapeutics has appointed Dennis Dean, Ph.D., as Executive Vice President and Head of Nonclinical Development. Dr. Dean will oversee preclinical research and development, ensuring the progression of drug candidates to clinical trials. His extensive experience in toxicology and pharmacology is expected to enhance the company's capabilities as it advances its portfolio.
Read more →Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to its Board of Directors
Odyssey Therapeutics has appointed Dr. Nia Tatsis to its Board of Directors. Dr. Tatsis, with over 20 years of experience in regulatory affairs, is expected to contribute significantly to the company's clinical development efforts. Odyssey aims to transform care for autoimmune and inflammatory diseases, and Dr. Tatsis's expertise will support their mission to advance their innovative pipeline.
Read more →Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
Odyssey Therapeutics has successfully closed a $213 million Series D financing round, with participation from existing and new investors. The funds will support the advancement of their clinical and preclinical programs targeting autoimmune diseases. The company aims to transform patient care through innovative therapies and has appointed new board members to enhance its governance.
Read more →Odyssey Therapeutics Appoints Jason Haas as Chief Financial Officer
Odyssey Therapeutics has appointed Jason Haas as Chief Financial Officer. With over two decades of experience in financial strategy and operations, Haas will play a key role in advancing the company's financial strategy and growth. His previous roles include CFO at Syros Pharmaceuticals and senior positions in investment banking. The company aims to transform care for autoimmune diseases.
Read more →Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies
Odyssey Therapeutics and Terray Therapeutics have announced a strategic collaboration to discover and develop small molecule therapies targeting transcription factors. This partnership leverages Odyssey's immunology expertise and Terray's advanced AI platform, tNova. The goal is to create innovative treatments for inflammatory diseases, sharing responsibilities and profits equally.
Read more →Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024
Odyssey Therapeutics will present new data on its RIPK2 scaffolding inhibitor, OD-07656, at the ACG Annual Scientific Meeting 2024. The presentation will highlight the compound's anti-inflammatory effects and its potential to work alongside standard therapies for inflammatory bowel disease. CEO Gary D. Glick emphasized the commitment to developing transformative treatments for patients.
Read more →Odyssey Therapeutics Appoints Biopharma Veterans Timothy P. Walbert and Ian F. Smith to its Board of Directors
Odyssey Therapeutics has appointed Timothy P. Walbert and Ian F. Smith to its Board of Directors. Both individuals bring extensive experience in the biopharmaceutical industry, with Walbert having led Horizon Therapeutics and Smith having played a key role at Vertex Pharmaceuticals. Their appointments are expected to enhance Odyssey's strategic growth as it advances its pipeline of precision medicines for inflammatory diseases.
Read more →